This review intends to describe recent studies on pancreatic tumor-associated stroma and potential opportunities and limitations to its targeting.
INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) is the fourth most common cause of cancer-related death, accounting for approximately 34 000 deaths each year in the United States, with an increasing annual incidence rate [1] . With an overall 5-year survival rate of less than 5%, death rates closely mirror incidence rates, reflecting the ineffectiveness of current therapies and the direness of the disease. A recent report has stated that if current trends continue, pancreatic cancer will become the second leading cause of cancer deaths in the United States by 2020 (http:/seer.cancer.gov/statfacts/html/pan creas.html, accessed May 2013). A small number of systemic therapies including Folfirinox, and a combination of gemcitabine and Abraxane, are reported to have modest clinical benefit over gemcitabine alone in the metastatic setting [2] [3] [4] [5] .
However, the prospects of cure, or even modest long-term survival, are essentially nonexistent in patients with advanced PDAC. Most adenocarcinomas of the pancreas are characterized by a dense fibrous stroma. Recent studies have been focusing on therapeutic targeting of the stroma to enhance drug penetration. It is becoming increasingly clear, however, that the unyielding stroma of pancreatic tumors does not simply act as a barrier to drug delivery, but as a complex signaling partner promoting tumorigenesis. The focus of the review is to update the reader about recent advances in the understanding of pancreatic cancer associated stroma, in which key questions remain, and to better understand the therapeutic implications of stromal targeting in pancreatic cancer.
CANCER-ASSOCIATED FIBROBLASTS IN STROMA
PDAC is one of the most stroma-rich cancers. Individual tumors show a wide range of growth rates and stromal content [6, 7] . PDAC stroma is very heterogeneous and comprises cellular and acellular components, such as fibroblasts, myofibroblasts, pancreatic stellate cells (PSC), immune cells, blood vessels, extracellular matrix (ECM), and soluble proteins such as cytokines and growth factors [8] . The fibrotic stroma in PDAC forms an environment that promotes cancer progression by enhancing pancreatic tumor growth as well as regional and distant metastasis [9] . Furthermore, the stroma has been shown to induce resistance to chemotherapy and radiation therapy [10] and to constitute a barrier to the delivery of therapeutic agents [11] . Whether depletion of the stroma would indeed result in regression of patient tumors has not been formally demonstrated. A possibility to consider based on the instructive role of mesenchyme in epithelial-mesenchymal interactions during development is that the mesenchyme (in this case tumorassociated stroma) might be secreting factors, that, in some instances, might affect the differentiation status of tumor cells, causing the tumor cells to differentiate, tilting the balance towards differentiation as opposed to proliferation. One example comes from a study showing the TGF-b target connective tissue growth factor (CTGF) expressing mesenchyme was associated with more highly differentiated tumors and better prognosis [12] .
In order to study the contributing role of the tumor stroma to pancreatic cancer biology, researchers have utilized stellate cells from rat and human pancreata [10, [13] [14] [15] [16] [17] . Stellate cells of the pancreas have an unknown origin, produce vitamin A droplets in the quiescent state, and develop a myofibroblast type appearance once activated. Whether all the fibroblasts within the stroma are derived from stellate cells has not been established. However, it is reasonable to expect that other components might contribute to the fibroblast population, including peri-vascular fibroblasts that become activated upon tissue injury and possibly bone-marrow derived cells. Stellate cells and other fibroblasts might be activated upon tissue injury and accumulate in the pancreas during carcinogenesis. So far, most studies addressing the functional roles of pancreatic cancer-associated fibroblasts (CAFs) have relied mainly on immortalized stellate cells, although one group has successfully cultured primary CAFs for functional studies as well [15] . These cells have been shown to enhance tumor growth, metastasis, and inhibit the effects of chemotherapy and radiation therapy on tumor cells [10, [15] [16] [17] . Interestingly, a subset of pancreatic CAFs have been shown to express the surface marker CD10, thus constituting a distinct subpopulation. CD10 expressing stellate cells were shown to induce an invasive phenotype in pancreatic cancer cells more extensively than cells lacking CD10 expression [13] . Despite this interesting finding, the mechanism by which CD10-expressing cells enhanced tumorigenesis was not interrogated. Overall, these studies suggest that stroma can enhance tumor growth and invasion.
MESENCHYMAL STEM CELLS IN STROMA
Mesenchymal stem cells (MSCs) have attracted great interest because their presence has recently been identified in human tumors and they have been shown to have the ability to migrate and engraft to areas of tumor development [18] . However, the role of MSCs during tumor growth appears to be exquisitely tissue-specific, with tumor-promoting or tumor-inhibiting effects observed in different settings. Recent studies in solid tumors of lung, stomach and ovary have identified MSCs associated with cancer and have described their tumor-enhancing properties [19] [20] [21] [22] [23] . MSCs have so far not been identified in pancreatic cancer, and therefore no information is available as to their potential role in the context of this disease.
KEY POINTS
Pancreatic cancer is characterized by a dense stroma.
The tumor-promoting roles of stroma have been documented.
Both the tumor and stroma promote immunosuppression.
Stromal cells and proteins may serve as prognostic and/or therapeutic biomarkers.
The stroma has emerged as a potential therapeutic target.
Mesenchymal stem cells drive cancer stem cells
Histologically, pancreatic cancer shows immense cellular heterogeneity within the same tumor, indicating a complex regulation of cancer progression. Our lab has previously identified and characterized pancreatic cancer stem cells (CSCs), and has demonstrated that the capacity of a tumor to grow and propagate is dependent on this small subset of cells [24] . A key question in the field has been whether these CSCs are a fixed population or if they might exhibit some plasticity and be responsive to cues from the microenvironment. To that end, a recent study has identified the contributions of bone marrow derived MSCs in regulation of EMT and in maintenance of a pancreatic tumor-initiating cell population [25] . MSCs treated with TGF-b showed enhanced ability to induce EMT and sphere formation in tumor-initiating cells. Furthermore, these effects by TGF-b treated MSCs were dependent on Notch signaling activity. It remains to be ascertained whether these results have relevance in the context of an intact pancreatic cancer microenvironment.
HEDGEHOG AND STROMA
Hedgehog signaling is absent in the normal adult pancreas, but is induced during PanIN (pancreatic intraepithelial neoplasia) formation and PDAC progression [26] . Three mammalian hedgehog genes have been identified as ligands: Sonic hedgehog (Shh), Indian hedgehog (Ihh), and Desert hedgehog (Dhh). These ligands can bind to the receptors Patched-1 (Ptch-1) and Patched-2 (Ptch-2). Hh ligands elicit their effects by antagonizing Patched activity. Hh binds Ptch and relieves Ptch inhibition of a transmembrane protein called Smoothened (Smo). Once Smo is activated, it acts through a protein complex to block proteolytic processing of a zinc finger transcription factor family called Gli. The proteolyzed form of Gli is a potent transcriptional repressor, but upon stabilization by Hh signals, full-length Gli translocates to the nucleus, where it binds and activates Hh target genes [27] . There are three Gli zinc finger transcription factors: Gli1, Gli2, and Gli3. Gli1 is completely dependent on Hh activity for its expression and primarily functions as an Hh activator [28] [29] [30] [31] [32] [33] . While Gli2 exhibits both activator and repressor activities, Gli3 is primarily a transcriptional repressor although transcriptional activator properties have been described [33] [34] [35] . Hh signaling in pancreatic cancer occurs in a paracrine mechanism with expression and secretion of Hh ligand in cancer cells and activation of the canonical signaling pathway in the adjacent stromal cells [36, 37] . This activation of Hh signaling in the stromal cells in turn supports tumor growth and metastasis. Recent reports show that Hh inhibition resulted in a decrease in the fibrous stroma. Hh signaling was inhibited using anti-Shh 5E1 antibody in orthotopic xenografts derived from pancreatic cancer cell lines which showed a decrease in desmoplasia, as measured by a decrease in smooth muscle actin (SMA) positive cells and reduced collagen deposition [38] . In a second report, Hh signaling was inhibited using the smoothened inhibitor (IPI-926, Infinity Pharmaceuticals) in a genetically engineered mouse model of PDAC. This study demonstrated not only a decrease in the fibrous stroma but an increase in the uptake and anticancer effects of gemcitabine [11] . These results led to a Phase II clinical trial using IPI-926, however the study was stopped early due to increased mortality in the treatment arm [NCT01130142 (clinical trials.gov)]. The reason for these discordant results in the genetically engineered mouse model and patients remains to be elucidated. In contrast to these studies, another study found that inhibition of Hh signaling using the anti-Shh 5E1 antibody in primary patient derived pancreatic cancer xenografts at orthotopic sites did not result in attenuation of the stroma [39] . These differences may be due to different levels of SHH production in the different models used, or alternatively it is possible that targeting different components of the Hh pathway may account for different effects of the tumor and its associated stroma [39] . Recently an elegant study detailed the role of Gli1 in Kras-induced carcinogenesis [40] . Loss of Gli1 in the pancreatic epithelium blocked the progression of Kras-induced PanIN lesions to pancreatic cancer. This effect was shown to be mediated by Gli1 regulation of IL-6. It was also shown that Kras-induced Shh expression in tumor cells led to activation of Gli1 in the stroma. Once activated, Gli1 was shown to bind to IL-6 promoter, thereby increasing its expression. IL-6 from the stroma then induced Stat3 activation in the tumor cells [40] . This study shows a clear mechanistic link between SHH production by neoplastic epithelial cells and the induction of stromagenesis in the pancreas by an IL-6/Stat3-related mechanism (Fig. 1 ).
IMMUNOSUPPRESSIVE CELLS IN STROMA
Immune cells are a significant part of pancreatic tumor-associated stroma and can be seen early during PDAC development [8] . PDAC creates a highly immunosuppressive tumor microenvironment through the production of inhibitory cytokines and recruitment of immunomodulatory cells Deci phering the role of stroma in pancreatic cancer Waghray et al. [8] . Recent reports have focused on the mechanism of recruitment of immunosuppressive cells to the site of tumor growth and the origin of immunosuppressive cells, also known as myeloid-derived suppressor cells (MDSC). The increased presence of MDSC in bone marrow and peripheral circulation of patients with PDAC has been correlated with disease stage. Furthermore, targeting MDSCs with zoledronic acid (a potent aminobisphosphonate that is known to target MDSC) in a genetically engineered mouse model of pancreatic cancer improved the host antitumor response, delayed tumor growth rate, prolonged median survival, and increased recruitment of T cells to the tumor, suggesting its therapeutic potential [41] . Two recent articles have demonstrated that Kras-induced GM-CSF production from tumor cells leads to recruitment of MDSC to tumor microenvironment. GM-CSF was shown to be necessary and sufficient in recruiting and in driving the development of MDSC [42 & ,43 & ]. Another group has shown that pancreatic cancer-associated stellate cells induce differentiation of MDSC in a Stat3-dependent manner via IL-6 signaling pathway [44] . Therefore, both the tumor and its associated stroma in PDAC cooperate in suppressing the host immune response. As a result, targeting the immune compartment of the tumor microenvironment may be beneficial in enhancing the antitumor response.
ONCOGENIC KRAS AND THE PANCREATIC CANCER STROMA
The use of genetically engineered mouse models of pancreatic cancer has opened the way to studying the initial steps of pancreatic tumorigenesis in the context of an intact microenvironment. The models that best represent the human disease rely on tissuespecific expression of an oncogenic form of Kras, KrasG12D, which is the most common mutation in human pancreatic cancer [6, 7] . The most commonly used model combines the Kras mutation with a mutant form of the tumor suppressor p53, and is frequently referred to as KPC mouse [45] . Analysis of the KPC mouse has shown that the accumulation of the fibrotic stroma and infiltrating immune cells accompanies the formation of pancreatic cancer from its early stages, represented by the precursor lesions known as PanINs [46] . Accumulation of the fibrotic stroma and the establishment of an immunosuppressive environment might be prerequisites for tumor progression. How these characteristics are established and maintained is still a matter of debate. Recent insight indicates that epithelial cells expressing oncogenic Kras provide signals that lead to accumulation of the stroma, proliferation of its components, and maintenance of the stroma over time. The recently described iKrasÃ mice [47] express KrasG12D in a tissue-specific manner. In contrast with KPC mice, KrasG12D expression in these animals is inducible and reversible. Thus, oncogenic Kras expression can be inactivated at any time, and the effects of this inactivation both on the epithelial cells and the surrounding stroma can be evaluated. Similarly to KPC mice, PanIN formation in iKrasÃ mice is accompanied by the accumulation of a fibroinflammatory stroma. Intriguingly, though, inactivation of Kras at the PanIN stage or in tumors is rapidly followed by suppression of proliferation within the stroma compartment, return of the fibroblasts to a quiescent state (characterized by loss of smooth muscle actin expression), and eventually remodeling of the extracellular matrix and elimination of the fibroblasts. In addition, the inflammatory infiltrates gradually decrease over time. The exact mechanisms mediating the relation between the oncogenic Kras-expressing tumor cells and the surrounding fibroblasts and immune cells are not fully elucidated. However, it is to be noted that Shh expression in the epithelial cells returns to basal (undetectable) levels upon Kras inactivation. It is however likely that multiple signaling pathways contribute to the changes in the stroma. In fact, the use of a reporter allele for the Hedgehog target gene Gli1 indicated that only a small subset of the fibroblasts within the stroma, and an even smaller subset of the immune cells, have active hedgehog signaling. Thus, Hedgehog signaling is not likely to be the only, or the prevalent, signal mediating epithelial-mesenchymal interactions in pancreatic cancer. The evidence that Kras inhibition results in remodeling of the stroma implies that it might be possible to target the stroma though targeting the tumor cells. Another aspect to consider is that the signals produced by the stroma and necessary for tumor growth are largely unknown; if identified, those signals might constitute other potential therapeutic targets.
STROMAL MARKERS AND PROGNOSIS
Stromal prognostic markers that may predict disease recurrence have recently received attention. The activated stroma index, defined as the ratio of myofibroblasts over collagen deposition, was shown to be an independent prognostic marker of survival in pancreatic cancer patients. A high stromal index as shown by increased number of myofibroblast cells correlated with poor survival, while in contrast, high collagen deposition was correlated with significantly better survival [48] . These findings are intriguing, and suggest the possibility that the amount of stromal deposition may influence tumor behavior in a way not previously expected. Further functional studies will be needed to validate the relevance of this finding in an independent patient cohort. The presence of tumor-associated macrophage (TAM) and neutrophil (TAN) cells in the tumor microenvironment has been shown to be a poor prognostic marker [49, 50] . Both TAM and TAN promote tumor cell invasiveness by breaking down ECM in PDAC [51] . Although some studies have focused on enumeration of different cell types within the pancreatic tumor microenvironment to identify potential prognostic and therapeutic markers, others have focused on the proteins expressed in these different cell types. One such study identified expression of fibroblast associated protein (FAP) in tumor adjacent myofibroblast cells and correlated it with poor prognosis [52] . More recently, expression of the kindlin-2 focal adhesion protein in peritumoral cancer-associated fibroblasts was associated with poor prognosis [53] . Additional analysis will be needed to discern the utility of specifically targeting individual cell types and/or their products as part of emerging treatment regimens.
CURRENT THERAPEUTIC STROMAL TARGETS
Although our understanding of tumor biology has facilitated the development of new cancer treatments, based on the growing body of data implicating a tumor-promoting role of the stroma, new therapeutic regimens including agents to target the stroma have been developed. In a recent paper by Provensano et al. [54] , the authors found that targeting hyalouronidase decreased the high interstitial pressure present in tumors and improved chemotherapy delivery with significant inhibition of tumor growth in the KPC model. A similar observation was made by Jacobetz et al. [55] . In addition, an antifibrotic drug, pirfenidone, known to exert antifibrotic effects by inhibiting fibroblasts and the production of TGF-b, PDGF, and collagen type I and currently approved for treatment of patients with pulmonary fibrosis, has recently been reported to inhibit tumor growth using a mouse model of PDAC [56] . Further, recent studies in humans have Deci phering the role of stroma in pancreatic cancer Waghray et al.
demonstrated that treatment with nab paclitaxel (also known as Abraxane), thought to deplete the stroma through effects on SPARC inhibition, inhibited tumor growth in PDAC patients [4] . A large, multicenter randomized Phase III prospective clinical trial was reported at ASCO GI this year showing that gemcitabine and Abraxane resulted in prolonged patient survival compared to gemcitabine alone [2] . Analysis of accompanying tumor samples will provide useful information to confirm if this treatment regimen exerts its antitumor effects through SPARC or effects on the stromal content of the tumor.
Mesenchymal stem cells as a therapeutic tool to bypass stroma in pancreatic cancer
Cell-based therapy is a novel therapeutic strategy for targeting solid tumors. MSCs in particular have shown promise as targeting moieties due to their ability to migrate and engraft to established tumor. Early studies using lentiviral vectors have demonstrated the ability of genetically modified, EGFP lentiviral transduced MSCs to migrate to sites of orthotopic tumors [57] . This was followed up by a study demonstrating that intravenous injection of MSCs expressing a CCL5 promoter driven Herpes simplex virus thymidine kinase (HSV-Tk) gene inhibited primary tumor growth by 50% and reduced liver metastasis compared with control lentiviral transduced MSCs [58] . In a recent study human pancreas derived MSCs were engineered with TRAIL to study its effects on pancreatic cancer cell lines. This study demonstrated that pancreas derived MSCs possess intrinsic ability to inhibit pancreatic cancer cells, which can be potentiated by TRAIL [59 & ].
CONCLUSION
Our understanding of pancreatic cancer is shifting from a disease of malignant tumor cells only towards a complex interactive tumor microenvironment ( Fig. 1 ). This recognition has increased the focus on the fibroinflammatory stroma of PDAC. It is clear that the extensive desmoplastic reaction observed in pancreatic cancer is a key feature of the biology of this disease. New therapeutic regimens are likely to incorporate agents that target components of the tumor microenvironment, including the stroma, along with the neoplastic epithelial compartment of the tumor. Further research is needed to best determine the optimal therapeutic approaches to most effectively target the heterogeneous cell populations in the tumor to eradicate the disease and improve patient survival.
